Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Reports More Positive Phase 3 Study Results for V114 Vaccine

10/20/2020 | 07:24am EST

By Colin Kellaher

Merck & Co. on Tuesday reported positive results for its V114 investigational 15-valent pneumococcal conjugate vaccine in two additional phase 3 studies.

The Kenilworth, N.J., drug maker said V114 met its primary immunogenicity objectives and elicited a strong immune response for all 15 serotypes included in the vaccine, including 22F and 33F, the two serotypes targeted by V114 but not by the currently available 13-valent pneumococcal conjugate vaccine.

Merck said V114 was generally well tolerated in both studies, with a safety profile consistent with that observed in previously reported studies.

Merck in September said a pair of phase 3 studies evaluating V114 had met their primary immunogenicity objectives.

The company said its plans for global regulatory licensure applications, beginning with the U.S. Food and Drug Administration before the end of the year, remain on track.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-20-20 0723ET

All news about MERCK & CO., INC.
08:46aMERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
AQ
08:46aCORCEPT THERAPEUTICS INCORPORATED : Appoints Gillian M. Cannon, PhD, to Board of..
AQ
08:46aMERCK : to Acquire OncoImmune
AQ
11/23GLOBAL MARKETS LIVE: Boeing’s 737 Max to resume flights in Europe, Merck’s la..
11/23MERCK : Correction to Merck to Buy OncoImmune Article
DJ
11/23Merck to Buy OncoImmune for $425 Million Amid Race for Covid-19 Treatments --..
DJ
11/23MERCK : Applies in U.S., Europe to License V114 Pneumococcal Conjugate Vaccine
DJ
11/23Merck to Buy OncoImmune Amid Covid-19 Vaccine Development
DJ
11/23MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
BU
11/23MERCK : to Acquire OncoImmune
BU
More news
Financials (USD)
Sales 2020 48 147 M - -
Net income 2020 11 964 M - -
Net Debt 2020 14 612 M - -
P/E ratio 2020 17,1x
Yield 2020 3,03%
Capitalization 203 B 203 B -
EV / Sales 2020 4,52x
EV / Sales 2021 4,18x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,05 $
Last Close Price 80,28 $
Spread / Highest target 33,3%
Spread / Average Target 19,6%
Spread / Lowest Target 5,88%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-11.73%203 111
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-3.77%283 004
PFIZER INC.-6.79%202 993
NOVARTIS AG-13.38%198 168
ABBVIE INC.15.41%180 396